Form 4: Renee P Tannenbaum Reports Acquisition of Stock Options in Cardiff Oncology, Inc.
SEC Form 4 Filing
Director Renee P Tannenbaum reports acquiring 29,700 stock options in Cardiff Oncology, Inc. on June 27, 2024.
Summary
- Renee P Tannenbaum, a director of Cardiff Oncology, Inc., filed a Form 4 with the SEC.
- The form reports a transaction that occurred on June 27, 2024.
- Tannenbaum acquired 29,700 stock options with an exercise price of $2.33.
- The options become exercisable on June 27, 2025, and expire on June 27, 2034.
- Following the reported transaction, Tannenbaum directly owns 128,201 shares of Cardiff Oncology, Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. It doesn't inherently indicate positive or negative news.
Positives
- The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of transaction: Acquisition of stock options. |
| 06/27/2025 | Date the stock options become exercisable. |
| 06/27/2034 | Expiration date of the stock options. |
| 07/01/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.